A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
Status:
Terminated
Trial end date:
2016-07-31
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the
efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the
prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients
who received antilymphocyte induction therapy.